MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Dramatic outcomes in prostate cancer study

Back to prostate Blogs list Cancer blog  


Subscribe To Prostate RSS Feed  RSS content feed What is RSS feed?

Dramatic outcomes in prostate cancer study




Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug treatment that was used in combination with standardized hormone therapy and radiation treatment. The men were participating in a clinical trial of an immunotherapeutic agent called MDX-010 or ipilimumab. In these two cases, physicians say the approach initiated the death of a majority of cancer cells and caused the tumors to shrink dramatically, allowing surgery. In both cases, the aggressive tumors had grown well beyond the prostate into the abdominal areas.



Dramatic outcomes in prostate cancer study

"The goal of the study was to see if we could modestly improve upon current therapys for advanced prostate cancer," says Eugene Kwon, M.D., Mayo Clinic urologist and leader of the clinical trial. "The candidates for this study were people who didn't have a lot of other options. However, we were startled to see responses that far exceeded any of our expectations".

The patients first received a type of hormone treatment called androgen ablation, which removes testosterone and commonly causes some initial reduction in tumor size. Scientists then introduced a single dose of ipilimumab, an antibody, which builds on the anti-tumor action of the hormone and causes a much larger immune response, resulting in massive death of the tumor cells. Both men experienced consistent drops in their prostate specific antigen (PSA) counts over the following weeks until both were deemed eligible for surgery. Then, during surgery, came a greater surprise.

"The tumors had shrunk dramatically," says Michael Blute, M.D., Mayo urologist, co-investigator and surgeon, who operated on both men. "I had never seen anything like this before. I had a hard time finding the cancer. At one point the pathologist (who was working during surgery) asked if we were sending him samples from the same patient".

One patient underwent radiation treatment after surgery; both have resumed their regular lives. Further research is being planned to understand more about the mechanisms of the antibody and how best to use the approach in practice. The researchers, however, note the significance of their findings.

"This is one of the holy grails of prostate cancer research," says Dr. Kwon. "We've been looking for this for years".


Posted by: Mark    Source




Did you know?
Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug treatment that was used in combination with standardized hormone therapy and radiation treatment. The men were participating in a clinical trial of an immunotherapeutic agent called MDX-010 or ipilimumab. In these two cases, physicians say the approach initiated the death of a majority of cancer cells and caused the tumors to shrink dramatically, allowing surgery. In both cases, the aggressive tumors had grown well beyond the prostate into the abdominal areas.

Medicineworld.org: Dramatic outcomes in prostate cancer study

Comprehensive| Diagnosis of bladder cancer| Follow up of bladder cancer| Bladder cancer main| Overview of bladder cancer| Risk factors for bladder cancer| Screening for bladder cancer| Symptoms of bladder cancer| Treatment of bladder cancer|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.